News Neurocrine Biosciences, Inc. Deutsche Boerse AG

Equities

NB3

US64125C1099

Market Closed - Deutsche Boerse AG Other stock markets 09:58:09 31/05/2024 pm IST			5-day change	1st Jan Change
124 ^EUR	+0.61%		-4.36%	+4.38%

31/05	Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	MT
28/05	Neurocrine Biosciences Says CEO Kevin Gorman Retiring	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	31/05	MT
Neurocrine Biosciences to Participate at Investor Conferences in June	30/05	PR
Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024	29/05	AQ
Neurocrine Biosciences Says CEO Kevin Gorman Retiring	29/05	MT
Neurocrine founder-CEO Gorman to retire in October	29/05	RE
Neurocrine CEO set to retire	29/05	RE
Neurocrine Biosciences Announces CEO Succession Plan	29/05	PR
Neurocrine Biosciences Announces CEO Changes	29/05	CI
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating	28/05	MT
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024	28/05	PR
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing	22/05	MT
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules	22/05	PR
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis	22/05	CI
Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	21/05	AQ
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing	17/05	MT
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	14/05
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024	14/05	PR
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024	14/05	CI
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	10/05	AQ
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024	09/05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Neurocrine Biosciences, Inc. Deutsche Boerse AG

Equities

NB3

US64125C1099

Summary

Filters